Gene Therapy for Hemophilia B can replace lifelong need for factor IX injections
Freeline Therapeutics has advanced a new gene therapy that can potentially replace the need for lifelong factor IX injections in patients with Hemophilia B. This could emerge as a game changer in the management of Hemophilia B, a hereditary bleeding disorder. The absence of factor IX which is a naturally produced protein known for its…
News ViewsMonkeypox is not new, but the pattern of outbreak is new and unprecedented
The first human case of Monkeypox can be dated back to 1970. Democratic Republic of Congo was the first country to report Monkeypox in humans back then. Since then, the disease caused by Monkeypox virus remained rare and contained within in the regions of central and western African countries. The recent outbreak of Monkeypox disease…
New Patent granted for Thermally-controlled DNA synthesis technology by Evonetix
Evonetix Ltd has completed yet another milestone in its pursuit of reimagining biology with proprietary DNA synthesis technologies. The company’s thermally controlled technology for DNA synthesis is now patented in Europe. This includes the design and manufacturing of its silicon chips. Evonetix has been relentlessly pursuing the development of a benchtop DNA synthesis platform. Such…
Novartis’s Pluvicto (radioligand therapy) is now FDA Approved for mCRPC treatment
The Swiss based Pharma Major scores yet another FDA approval for its new radioligand therapy. This much anticipated regulatory nod was received this week, enabling the global innovator to offer a new treatment paradigm. mCRPC is the short form for metastatic castration resistant prostate cancer. Prostate cancer is the most common cancer type in men….
Nanopore DNA sequencing – New genetic test to diagnose Rare Neurological Diseases
Diagnosing some of the rare or hidden neurological disorders has been a challenge to the medical fraternity for long. Several conditions are often presented with similar set of symptoms. Inaccurate diagnosis is one of the top-most reasons for treatment delays.Nanopore DNA sequencing is a new DNA test that can effectively diagnose over fifty genetic disorders…
How is it looking for CAR-T and Gene Therapies so far in 2022?
With almost a quarter gone by in 2022, it would be a natural tendency for the Gene Therapy enthusiasts and market observers to try and make some sense of the developments in the sector. For some it could be a mixed bag of experiences and ardent expectations at the same time. It is a mixed…
Pfizer’s RSV vaccine granted FDA Breakthrough Therapy Status
Pfizer has secured the Breakthrough designation for its RSV vaccine RSVpreF this week. The US FDA has granted RSVpreF this coveted status base on a phase 2b proof of concept study. This also comes at a time when GSK, another player in this segment has faced a setback after the safety assessment of its vaccine….
Pramipexole-Rasagiline Combination Promising for Early Parkinson Disease Treatment
A novel combination of Pramipexole-Rasagiline is found to be promising in a recently concluded clinical trial for Early Parkinson Disease treatment. Top line results from this Phase III trial indicate the superiority of fixed-dose combination of extended release (ER) formulations of pramipexole and rasagiline (P2B001) in adults with early Parkinson disease. P2B001 has successfully met…
Livtencity (maribavir) by Takeda – FDA Approved Drug for Cytomegalovirus treatment
Livtencity is the first drug to be approved by US FDA for the treatment of Cytomegalovirus. This approval is specifically for the use in patients with post-transplant cytomegalovirus (CMV) infection or disease, failing to respond to the available antiviral treatments. Livtencity’s FDA approval is awarded with Breakthrough Therapy and Priority Review Designations. Livtencity works by…
Molnupiravir for COVID-19 – Is it a Magic Pill or just a Hype in the Making?
Merck’s Molnupiravir, an oral antiviral treatment is set for review by the FDA Advisory Panel. If approved, Molnupiravir will be the first oral antiviral treatment authorized for the treatment of COVID-19. This experimental drug was developed by Merck and Ridgeback Biotherapeutics. This comes at the back drop of several drugs failing to prove their efficacy,…